{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:40Z","timestamp":1793041960535,"version":"4.5.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Global Services, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.1080\/14712598.2024.2352591","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:59:03Z","timestamp":1715590743000},"page":"339-350","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[{"name":"Multiple Myeloma Division, Tisch Cancer Institute, Mount Sinai Medical Center New York, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Sun","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010155"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072160"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.005"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1317"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2081147"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211019622"},{"key":"e_1_3_6_11_1","unstructured":"Janssen Biotech Inc and Legend Biotech. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf"},{"key":"e_1_3_6_12_1","unstructured":"Janssen Biotech Inc and Legend Biotech. CARVYKTI\u00ae (ciltacabtagene autoleucel) summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01301-8"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8010"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00289-7"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178882"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178806"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012336"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8005"},{"key":"e_1_3_6_27_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) version 3. 2024 [cited 2024 Mar 8]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703233"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106576"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26602"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00797-8"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846468.64341.f1"},{"key":"e_1_3_6_40_1","first-page":"P","volume-title":"19th International Myeloma Society (IMS) Annual Meeting","author":"Dhakal B","year":"2022","unstructured":"Dhakal B, Einsele H, Potluri R, et al. Real-world treatments and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma treated with 1\u20133 prior lines of therapy, including a PI and IMiD, from the SEER-Medicare database. In: 19th International Myeloma Society (IMS) Annual Meeting; Los Angeles, CA, USA; 2022. p. P\u2013240."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)00571-7"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182175"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019531"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26512"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.3.869.869"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.5.1298.1298"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007522"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.027"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071929"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"e_1_3_6_59_1","unstructured":"Janssen Research & Development. A study of JNJ-68284528 a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with multiple myeloma (CARTITUDE-2). [cited 2023 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03548207"},{"key":"e_1_3_6_60_1","unstructured":"Janssen Research & Development. A study of bortezomib lenalidomide and dexamethasone (VRd) followed by cilta-cel a CAR-T therapy directed against BCMA versus VRd followed by lenalidomide and dexamethasone (Rd) therapy in participants with newly diagnosed multiple myeloma for whom ASCT is not planned as initial therapy (CARTITUDE-5). [cited 2023 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04923893"},{"key":"e_1_3_6_61_1","unstructured":"European Myeloma Network. A study of daratumumab bortezomib lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab bortezomib lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma (CARTITUDE-6). [cited 2023 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05257083"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1953456"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283888"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8012"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.10.001"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159969"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146646"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8013"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2352591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:45:15Z","timestamp":1727225115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2352591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"alternative-id":["10.1080\/14712598.2024.2352591"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2352591","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}